Successful treatment of infliximab-associated immune-mediated sensory polyradiculopathy with intravenous immunoglobulin.

Abstract

Infliximab, a tumor necrosis factor-alpha antagonist, is used to treat many inflammatory diseases. Various forms of demyelinating neuropathies have been reported as neurological complications associated with infliximab use. There have been few reports of pure sensory neuropathy associated with infliximab. We report the clinical, electrophysiological, and pathological findings of a patient with subacute sensory polyradiculopathy 1 month after infliximab therapy for psoriasis vulgaris. Immune-mediated pathogenesis was suggested by positive anti-ganglioside antibodies and rapid response to intravenous immunoglobulin. This is the first reported case of sensory polyradiculopathy with positive anti-ganglioside antibodies following infliximab therapy. Our findings suggest the clinical importance of immunological investigations and treatment in demyelinating neuropathies following infliximab therapy.

• Authors: Hiroya Naruse, Yu Nagashima, Risa Maekawa, Takafumi Etoh, Ayumi Hida, Jun Shimizu, Ken-ichi Kaida, Yasushi Shiio
• Journal: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (J Clin Neurosci) Vol. 20 Issue 11 Pg. 1618-9 (Nov 2013) ISSN: 1532-2653 [Electronic] Scotland
• PMID: 23906523 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2013 Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Antibodies, Monoclonal
• Immunoglobulins, Intravenous
• Infliximab

Topics

• Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
• Antibodies, Monoclonal (adverse effects)
• Comorbidity
• Diabetes Mellitus, Type 2 (epidemiology)
• Humans
• Hypertension (epidemiology)
• Immunoglobulins, Intravenous (therapeutic use)
• Infliximab
• Male
• Middle Aged
• Polyradiculopathy (chemically induced, drug therapy, pathology)
• Psoriasis (drug therapy)